Pub Date : 2020-10-09DOI: 10.21203/rs.3.rs-88713/v1
Jialin Yu, Chang-lu Wang, Yuan Liu, Jia-ming Wang, C. Lv, Jun Liu, Zhang Qin, X. Fu, Xuwei Cai
PURPOSE To identify the valuable predictors of grade≥2 radiation pneumonitis (RP) in patient treated with radiotherapy after pneumonectomy for non-small cell lung cancer (NSCLC); and to construct a nomogram predicting the incidence of grade≥2 RP in such patients. PATIENTS AND METHODS We reviewed 82 patients with NSCLC received radiotherapy after pneumonectomy from 2008 to 2018. The endpoint was grade≥2 RP. Univariate and multivariate regression analysis were conducted to evaluate significant factors of grade≥2 RP. Receiver operating characteristic (ROC) curve was used to establish optimal cutoff values and the nomogram was built to make the predictive model visualized. Descriptive analysis was performed on 5 patients with grade 3 RP. RESULTS A total of 22(26.8%) patients developed grade 2 RP and 5(6.1%) patients were grade 3 RP. V5, V10, V20, V30, MLD, PTV, and PTV/TLV were associated with the occurrence of grade≥2 RP in univariate analysis, while none of the clinical factors was significant; V5(OR,1.213;95%CI,1.099-1.339; P<0.001) and V20(OR,1.435;95%CI,1.166-1.765; P=0.001) were the independent significant predictors by multivariate analysis and were included in the nomogram. The ROC analysis for the cutoff values for predicting grade≥2 RP were V5>23% (AUC=0.819, sensitivity:0.701, specificity:0.832) and V20>8% (AUC=0.812, sensitivity:0.683, specificity:0.811). Additionally, grade≥3 RP did not occur when V5<30%, V20<13% and MLD<751.2cGy, respectively. CONCLUSIONS Our study showed that V5 and V20 were independent predictors for grade≥2 RP in NSCLC patients receiving radiotherapy after pneumonectomy. Grade 3 RP did not occur whenV5<30%, V20<13% and MLD<751.2cGy, respectively. In addition, patient underwent right pneumonectomy may have a lower tolerance to radiation compared to left pneumonectomy.
目的探讨非小细胞肺癌(NSCLC)全肺切除术后放疗患者发生≥2级放射性肺炎(RP)的有价值预测因素;并构建预测此类患者≥2级RP发生率的nomogram。患者与方法回顾性分析了2008年至2018年收治的82例非小细胞肺癌全肺切除术后放疗患者。终点为≥2级RP。采用单因素和多因素回归分析评价RP≥2级的显著性因素。采用受试者工作特征(ROC)曲线建立最佳截止值，并建立nomogram使预测模型可视化。对5例3级RP患者进行描述性分析。结果2级RP 22例(26.8%)，3级RP 5例(6.1%)。在单因素分析中，V5、V10、V20、V30、MLD、PTV、PTV/TLV与≥2级RP的发生相关，而临床因素均无统计学意义;V5(优势比,1.213;95%置信区间,1.099 - -1.339;P23% (AUC=0.819，敏感性:0.701，特异性:0.832)，V20>8% (AUC=0.812，敏感性:0.683，特异性:0.811)。此外，V5<30%、V20<13%和MLD<751.2 g gy时，均未发生≥3级RP。结论我们的研究表明V5和V20是肺切除术后接受放疗的非小细胞肺癌患者≥2级RP的独立预测因子。当v5 <30%， V20<13%， MLD<751.2 g gy时，未发生3级RP。此外，与左侧全肺切除术相比，右侧全肺切除术患者对放射的耐受性可能较低。
{"title":"Study of the predictors for radiation pneumonitis in patient with non-small cell lung cancer received radiotherapy after pneumonectomy.","authors":"Jialin Yu, Chang-lu Wang, Yuan Liu, Jia-ming Wang, C. Lv, Jun Liu, Zhang Qin, X. Fu, Xuwei Cai","doi":"10.21203/rs.3.rs-88713/v1","DOIUrl":"https://doi.org/10.21203/rs.3.rs-88713/v1","url":null,"abstract":"PURPOSE\u0000To identify the valuable predictors of grade≥2 radiation pneumonitis (RP) in patient treated with radiotherapy after pneumonectomy for non-small cell lung cancer (NSCLC); and to construct a nomogram predicting the incidence of grade≥2 RP in such patients.\u0000\u0000\u0000PATIENTS AND METHODS\u0000We reviewed 82 patients with NSCLC received radiotherapy after pneumonectomy from 2008 to 2018. The endpoint was grade≥2 RP. Univariate and multivariate regression analysis were conducted to evaluate significant factors of grade≥2 RP. Receiver operating characteristic (ROC) curve was used to establish optimal cutoff values and the nomogram was built to make the predictive model visualized. Descriptive analysis was performed on 5 patients with grade 3 RP.\u0000\u0000\u0000RESULTS\u0000A total of 22(26.8%) patients developed grade 2 RP and 5(6.1%) patients were grade 3 RP. V5, V10, V20, V30, MLD, PTV, and PTV/TLV were associated with the occurrence of grade≥2 RP in univariate analysis, while none of the clinical factors was significant; V5(OR,1.213;95%CI,1.099-1.339; P<0.001) and V20(OR,1.435;95%CI,1.166-1.765; P=0.001) were the independent significant predictors by multivariate analysis and were included in the nomogram. The ROC analysis for the cutoff values for predicting grade≥2 RP were V5>23% (AUC=0.819, sensitivity:0.701, specificity:0.832) and V20>8% (AUC=0.812, sensitivity:0.683, specificity:0.811). Additionally, grade≥3 RP did not occur when V5<30%, V20<13% and MLD<751.2cGy, respectively.\u0000\u0000\u0000CONCLUSIONS\u0000Our study showed that V5 and V20 were independent predictors for grade≥2 RP in NSCLC patients receiving radiotherapy after pneumonectomy. Grade 3 RP did not occur whenV5<30%, V20<13% and MLD<751.2cGy, respectively. In addition, patient underwent right pneumonectomy may have a lower tolerance to radiation compared to left pneumonectomy.","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77014012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-05-19DOI: 10.1016/j.canrad.2020.03.001
J. Bouter, J. Lacroix, J. Baud, J. Thariat
{"title":"[MRI can be prescribed in patients with implanted cardiac devices (pacemaker, defibrillator) to optimize radiotherapy planning].","authors":"J. Bouter, J. Lacroix, J. Baud, J. Thariat","doi":"10.1016/j.canrad.2020.03.001","DOIUrl":"https://doi.org/10.1016/j.canrad.2020.03.001","url":null,"abstract":"","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":"61 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84568919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-04-01DOI: 10.1097/ju.0000000000000856
P. Bey, V. Beckendorf, J. Stines
Radiation therapy of prostate carcinoma with a curative intent implies to treat the whole prostate at high dose (at least 66 Gy). According to clinical stage, PSA level, Gleason's score, the clinical target volume may include seminal vesicles and less often pelvic lymph nodes. Microscopic extracapsular extension is found in 15 to 60% of T1-T2 operated on, specially in apex tumors. On contrary, cancers developing from the transitional zone may stay limited to the prostate even with a big volume and with a high PSA level. Zonal anatomy of the prostate identifies internal prostate, including the transitional zone (5% of the prostate in young people). External prostate includes central and peripheral zones. The inferior limit of the prostate is not lower than the inferior border of the pubic symphysis. Clinical and radiological examination: ultrasonography, nuclear magnetic resonance (NMR), CT-scan identify prognostic factors as tumor volume, capsule effraction, seminal vesicles invasion and lymph node extension. The identification of the clinical target volume is now done mainly by CT-Scan which identifies prostate and seminal vesicles. NMR could be helpful to identify more precisely prostate apex. The definition of margins around the clinical target volume has to take in account daily reproducibility and organ motion and of course the maximum tolerable dose for organs at risk.
{"title":"[Prostate cancer].","authors":"P. Bey, V. Beckendorf, J. Stines","doi":"10.1097/ju.0000000000000856","DOIUrl":"https://doi.org/10.1097/ju.0000000000000856","url":null,"abstract":"Radiation therapy of prostate carcinoma with a curative intent implies to treat the whole prostate at high dose (at least 66 Gy). According to clinical stage, PSA level, Gleason's score, the clinical target volume may include seminal vesicles and less often pelvic lymph nodes. Microscopic extracapsular extension is found in 15 to 60% of T1-T2 operated on, specially in apex tumors. On contrary, cancers developing from the transitional zone may stay limited to the prostate even with a big volume and with a high PSA level. Zonal anatomy of the prostate identifies internal prostate, including the transitional zone (5% of the prostate in young people). External prostate includes central and peripheral zones. The inferior limit of the prostate is not lower than the inferior border of the pubic symphysis. Clinical and radiological examination: ultrasonography, nuclear magnetic resonance (NMR), CT-scan identify prognostic factors as tumor volume, capsule effraction, seminal vesicles invasion and lymph node extension. The identification of the clinical target volume is now done mainly by CT-Scan which identifies prostate and seminal vesicles. NMR could be helpful to identify more precisely prostate apex. The definition of margins around the clinical target volume has to take in account daily reproducibility and organ motion and of course the maximum tolerable dose for organs at risk.","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":"36 1","pages":"560-70"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83615329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-01DOI: 10.1016/j.canrad.2019.08.005
A. Burgun
{"title":"[Basis and perspectives of artificial intelligence in radiation therapy].","authors":"A. Burgun","doi":"10.1016/j.canrad.2019.08.005","DOIUrl":"https://doi.org/10.1016/j.canrad.2019.08.005","url":null,"abstract":"","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77986904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-01DOI: 10.1016/j.canrad.2019.07.134
C. Verry, Erika Porcel, Cyrus Chargari, C. Rodriguez-Lafrasse, J. Balosso
{"title":"[Use of nanoparticles as radiosensitizing agents in radiotherapy: State of play].","authors":"C. Verry, Erika Porcel, Cyrus Chargari, C. Rodriguez-Lafrasse, J. Balosso","doi":"10.1016/j.canrad.2019.07.134","DOIUrl":"https://doi.org/10.1016/j.canrad.2019.07.134","url":null,"abstract":"","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":"68 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86031647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-31DOI: 10.1016/j.canrad.2019.06.013
K. Hadadi, M. Hommadi, M. Belemlih, N. Zaghba, Abdelhak Maghous, El-Amin Marnouch, K. A. Saghir, M. Elmarjany, H. Sifat, M. Oukabli, H. Mansouri
{"title":"[Solitary bone plasmocytoma: Experience from the radiotherapy department at Mohammed-V military teaching hospital in Rabat (Morocco)].","authors":"K. Hadadi, M. Hommadi, M. Belemlih, N. Zaghba, Abdelhak Maghous, El-Amin Marnouch, K. A. Saghir, M. Elmarjany, H. Sifat, M. Oukabli, H. Mansouri","doi":"10.1016/j.canrad.2019.06.013","DOIUrl":"https://doi.org/10.1016/j.canrad.2019.06.013","url":null,"abstract":"","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78687543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-12DOI: 10.1016/j.canrad.2019.09.001
D. Gensanne, A. Henni, Y. Lauzin, P. Clarisse, S. Thureau
{"title":"[Inter- and intrafraction imaging during stereotactic body radiation therapy: Which solutions for which tumours?]","authors":"D. Gensanne, A. Henni, Y. Lauzin, P. Clarisse, S. Thureau","doi":"10.1016/j.canrad.2019.09.001","DOIUrl":"https://doi.org/10.1016/j.canrad.2019.09.001","url":null,"abstract":"","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":"413 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75860110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-12DOI: 10.1016/j.canrad.2019.08.008
S. Ferreira, M. Dutreix
{"title":"DNA repair inhibitors to enhance radiotherapy: Progresses and limitations.","authors":"S. Ferreira, M. Dutreix","doi":"10.1016/j.canrad.2019.08.008","DOIUrl":"https://doi.org/10.1016/j.canrad.2019.08.008","url":null,"abstract":"","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86632617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-11DOI: 10.1016/j.canrad.2019.05.016
B. Ledoux, M. Dupont, F. Duplaquet, L. Pirard, S. Ocak, M. Wanet, V. Remouchamps
{"title":"Illustration of a fatal radiation-induced lung aneurysm: Is central lung stereotactic radiotherapy to be banned?","authors":"B. Ledoux, M. Dupont, F. Duplaquet, L. Pirard, S. Ocak, M. Wanet, V. Remouchamps","doi":"10.1016/j.canrad.2019.05.016","DOIUrl":"https://doi.org/10.1016/j.canrad.2019.05.016","url":null,"abstract":"","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":"51 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89980793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-11DOI: 10.1016/j.canrad.2019.09.002
S. Rivera, J. Hannoun-levi
{"title":"Hypofractionated radiation therapy for invasive breast cancer: From moderate to extreme protocols.","authors":"S. Rivera, J. Hannoun-levi","doi":"10.1016/j.canrad.2019.09.002","DOIUrl":"https://doi.org/10.1016/j.canrad.2019.09.002","url":null,"abstract":"","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":"90 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88277944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：